Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

Novartis paid out $195 million in 2020 to settle a criminal claim brought by the federal government – at the time, the ...

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new company, focused on central ...

The last mega-mergers between big pharma companies were BMS' $74 billion deal with Celgene in 2019 and the $63 billion AbbVie ...

Analysts said the ZEUS failure makes ziltivekimab a high-risk asset and increases the pressure on Novo Nordisk to carry out ...

Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial. The REACH-DMD study of pizuglanstat ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago. The US regulator has ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD).

A cancer patient in the US has filed a class action lawsuit against Novartis in the US, claiming that the company shared her private health information with third-party companies, including Google and ...